Hepatitis

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

The US Food and Drug Administration (FDA) has expanded the indication of the pangenotypic direct-acting antiviral (DAA) combination, glecaprevir/pibrentasvir (Mavyret®; AbbVie Inc., North Chicago, IL, USA), to include the treatment of acute hepatitis C virus (HCV) infection in adults ...

The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

The World Health Organization (WHO) has introduced updated guidelines for managing chronic hepatitis B, with the goal of enhancing testing, diagnosis and treatment, revealed at the 2024 Asian Pacific Conference for the Study of Liver Disease. These guidelines expand recommendations to include teenagers and emphasize patient choice and aim to simplify treatment decisions and improve access to care, particularly in resource-limited areas, by allowing treatment initiation without extensive viral testing.

Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal ...

Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key ...

A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges ...

There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. ...